Sponsored Links
| Repligen Reports Phase 2b Results For RG2417 For Bipolar Depression |
 |
 |
 |
| Medical News - Bipolar | |||
|
Repligen Corporation (NASDAQ: RGEN) announced results of a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. The study did not demonstrate a statistically significant improvement in the symptoms of depression in all patients receiving RG2417 when compared to placebo over the eight-week treatment period... Read more: Bipolar News From Medical News Today
|